Head-to-head comparison of current drug-eluting stents (DES) showed contradictory results that led us to believe, for years, that we had reached a plateau. This feeling was also fostered by the disappointment caused by Absorb and bioresorbable-polymer stents. However, this recent article featured in JACC Interventions shows a light at the end of the tunnel with...
We recently published the success of balloon-expandable Sapien valve when used as mitral valve replacement. We now hear about its success as pulmonary valve replacement. Previous experiences with this prosthesis for aortic valve replacement have encouraged many operators to attempt fixing other valves. At first, there were exceptional cases considered compassionate treatments. However, experience has...
Using Sapien 3, transcatheter mitral valve replacement to treat failed bioprosthetic valves can be performed with a high degree of technical success. Failed mitral bioprosthetic valves are truly challenging due to how frequent symptoms are and the high morbidity/mortality associated with a new surgical replacement. Furthermore, there are no catheter options specifically designed to treat this...
This final report published in NEJM about the efficacy of remdesivir against COVID-19 infection vs placebo showed its superiority though only in soft end points, which does not seem to modify the course of this pandemic. Multiple drugs initially promising have been shown ineffective against the new virus. The case of hydroxychloroquine resulted paradigmatic: not...
After 10 years, unstable or chronic coronary patients revascularized with drug-eluting stents (DES) had similar, very good outcomes regardless of whether the DES did or did not have a polymer, according to the ISAR-TEST-5 study, recently published in J Am Coll Cardiol. The 10-year device-oriented endpoints occurred in 43.8% of patients treated with a polymer-free sirolimus-eluting...
This work supports previous observations on the mortality benefit of regional (and even local) anesthesia in patients who undergo elective endovascular aneurysm repair for the treatment of infrarenal abdominal aortic aneurysms. These benefits also translated into a shorter hospital stay, but not into less pulmonary complications, which is what previous studies had suggested. Minimally invasive...
Low grade inflammation shown by elevated plasma concentrations of high-sensitive C-reactive protein are a risk factor for coronary artery disease (CAD) patients. There is also evidence to support low grade inflammation could be related to higher risk of cancer. This prospective study evaluated the relation between low grade systemic inflammation and the risk of cancer in...
The GLOBAL LEADERS study includes a pre-specified sub-study, GLASSY, that showed that ticagrelor monotherapy after one month of dual antiplatelet therapy is non-inferior (but not superior) to conventional treatment in terms of ischemic events. As regards safety, ticagrelor monotherapy did not decrease major bleeding compared with conventional therapy. The GLOBAL LEADERS randomized 15,991 patients who required...
Article published in the OH Magazine! / The Times on 09/09/2019. Access the article HERE Source: OH! Magazine: “Avances y desafíos de la Cardiología Intervencionista”.
Courtesy of SBHCI. This study showed that using the everolimus eluting stent with bioabsorbable polymer Synergy followed by 4 months of dual antiplatelet therapy (DAPT) to treat left main stenosis (LMS) was safe and effective, compared against using the everolimus eluting stent with permanent polymer Xience followed by the conventional 12 months DAPT. This study...